From 439 screened, a vetted short list of what a GI clinician should know, each
labeled by why it matters and led by the clinical takeaway. Filter by focus, topic, or
evidence strength; jump to a subspecialty from the left.
Clinical takeawaySystematically assess disability in all IBD patients, including those in remission, using validated tools like the IBD Disk or IBD-Disability Index, as disability persists even in inactive disease.
What it foundThe pooled prevalence of moderate-to-severe disability in IBD patients is 29.6%, higher in Crohn disease (36.9%) vs. ulcerative colitis (30.8%) and in active disease (56.9%) vs. inactive disease (27.0%).
ContextThis study confirms the high burden of disability in IBD, particularly in Crohn disease and active disease, and highlights the need for routine disability assessment, which is not yet standard practice.
Clinical takeawayIntensified infliximab dosing (10 mg/kg) may reduce colectomy risk in acute severe ulcerative colitis, but larger prospective trials are needed to confirm benefit and refine dosing strategies.
What it foundIntensified infliximab dosing (10 mg/kg) cut 3-month colectomy rate to 6% vs 27% with standard dosing (5 mg/kg) in acute severe ulcerative colitis.
ContextConfirms and refines prior mixed evidence on intensified dosing efficacy, using Bayesian methods to integrate retrospective and trial data (PREDICT-UC).
Clinical takeawayConsider SB012 enema for glucocorticoid-free UC patients, but await larger trials for broader validation.
What it foundIn glucocorticoid-free patients, SB012 enema (GATA3-targeting DNAzyme) improved Total Mayo Score by -2.2 vs placebo (P=0.027), but no effect was seen with corticosteroids (P=0.004 vs baseline in SB012 group).
ContextChallenges current UC therapies by targeting GATA3, a novel mechanistic approach, but efficacy signal is limited to steroid-naive patients.
Clinical takeawayReview the full ECCO guidelines for updated recommendations on medical treatment of ulcerative colitis, as they synthesize current evidence into clinical practice standards.
What it foundThe abstract does not report specific key results or effect sizes, as it is a guideline review rather than a study with new data.
ContextThis updates prior ECCO guidelines, reflecting new evidence and consensus on UC therapeutics since the last version.
Clinical takeawayReview and implement the updated ECCO guidelines for infection prevention, diagnosis, and management in IBD patients, particularly focusing on recommendations for vaccination, screening, and antimicrobial prophylaxis in immunocompromised individuals.
What it foundThe abstract does not report specific numerical results or effect sizes, as it is a guideline review.
ContextThese guidelines consolidate and update prior evidence and recommendations, providing a comprehensive approach to infection management in IBD, which is critical given the immunosuppressive therapies commonly used.
Clinical takeawayNo clinical action yet: a mechanistic finding in humans without specified interventions or outcomes.
What it foundThe study identifies nocturnal insulin resistance and reduced insulin availability in humans with MASLD.
ContextThis study adds to the understanding of metabolic disturbances in MASLD, particularly highlighting the timing of insulin resistance, which was previously understudied in this population.
Clinical takeawayPrognostic scores may help identify patients unlikely to benefit from standard adherence support. For elevated-risk patients, alternative strategies are needed as current adherence support did not improve outcomes.
What it foundIn minimal-risk hepatitis C patients, high-intensity adherence support (patient navigation + flexible directly observed therapy) showed a small SVR increase to 68.3% vs. 62.6% with low-intensity support (aRR 1.09, 95% CI: 1.00-1.19; p=0.04), but no benefit was seen in elevated-risk patients (SVR 50.8% vs. 48.4%).
ContextThis trial demonstrates that adherence support effectiveness varies by patient risk profile, but the clinical significance of the minimal-risk group difference is uncertain.
Clinical takeawayNo clinical action yet: a mechanistic finding in mice and human correlative data. Future clinical trials could explore anserine supplementation in cirrhotic patients with bacterial infections.
What it foundAnserine supplementation restored antibacterial immunity in cirrhotic mice by upregulating hepatocyte CCL5, leading to reduced bacterial burden and mortality, with human data showing correlations between CCL5, anserine, and CD44+ pDC levels with infection outcomes.
ContextPrior understanding centered on broad immune dysfunction in cirrhosis, but this study identifies a specific CD44+ pDC subpopulation defect and a metabolic-immune axis (anserine-CCL5-pDC-macrophage) as critical for antibacterial defense.
Clinical takeawayContinue standard UDCA dose (13-15 mg/kg/day) in PBC patients with complete biochemical response; reduction to 5 mg/kg/day is unsafe due to high relapse risk. Consider monitoring 10 mg/kg/day cautiously in select patients (future studies needed). Do not reduce below 10 mg/kg/day in remission.
What it foundIn PBC patients with complete biochemical response (Paris-II criteria), reducing UDCA to 5 mg/kg/day increased 12-month relapse to 19.4% vs 0% on standard dose (13-15 mg/kg/day), while 10 mg/kg/day showed no significant difference (2.9% relapse).
ContextChallenges prior uncertainty about UDCA dose reduction safety in remission; confirms standard dose remains gold standard but introduces 10 mg/kg/day as a potential future option if validated.
Journal of gastroenterology and hepatology · PubMed ↗
Clinical takeawayConsider heightened awareness for AITD symptoms in childhood-onset EoE patients (HR 2.53 for future AITD, OR 4.71 for prior AITD). No routine screening recommended for adult-onset EoE (HR 1.18, 95% CI 0.91-1.54).
What it foundEoE patients had a 29% higher prevalence of prior AITD (3.9% vs 3.0%, OR 1.29), while future AITD risk was similar (HR 1.18), except in childhood-onset EoE (HR 2.53 for future AITD, OR 4.71 for prior AITD).
ContextConfirms exploratory studies suggesting an EoE-AITD link but clarifies this is primarily in childhood-onset cases, refining prior uncertain evidence. Adult-onset association remains statistically inconclusive.
United European gastroenterology journal · PubMed ↗
New evidenceretrospective · n=164,987 · Jul 8, 2026
Clinical takeawayCounsel patients with DM or obesity starting GLP-1 analogs about the high likelihood (1 in 3) of GI side effects, particularly nausea, vomiting, and GERD, and monitor for gastroparesis symptoms (early satiety, bloating). Note the reduced bowel obstruction risk and no significant increase in ER visits or hospitalizations despite higher EGD use.
What it foundGLP-1 therapy was associated with a 31.9% rate of GI adverse events at one year (NNH 17.2), including nausea/vomiting (HR 1.24), GERD (HR 1.18), and gastroparesis (HR 1.57), while reducing bowel obstruction risk (HR 0.86).
ContextConfirms and quantifies real-world GI risks of GLP-1 analogs beyond clinical trial data, while challenging assumptions about healthcare utilization (lower admissions despite more EGDs). Prior evidence focused on GLP-1 benefits with less emphasis on AEs.
Clinical takeawayAdopt pRECIST criteria for consistent response assessment in pancreatic cancer clinical trials, particularly those testing neoadjuvant therapies, to ensure uniform data collection and interpretation.
What it foundpRECIST provides standardized definitions for pancreatic tumor response assessment using CT/PET scans, with independent reader adjudication resolving disagreements.
ContextRefines RECIST 1.1 by incorporating metabolic activity (PET) alongside tumor size (CT) for pancreatic cancer, addressing prior variability in response assessment.
Clinical takeawayNo clinical action yet: the abstract does not provide specific efficacy or safety data to support a change in practice. Further details from the full study are needed to assess its clinical applicability.
What it foundDaraxonrasib showed positive results in previously treated metastatic pancreatic cancer (specific numbers or effect size not provided in abstract).
ContextMetastatic pancreatic cancer has limited treatment options after first-line therapy, and new therapies are urgently needed. This study may introduce a potential new option pending full data review.
Clinical takeawayFor resectable pancreatic or periampullary disease in eligible patients at high-volume centers, consider robotic pancreatoduodenectomy (RPD) as a non-inferior alternative to open surgery (OPD) for potentially faster recovery and reduced complications.
What it foundRobotic pancreatoduodenectomy (RPD) showed faster postoperative functional recovery than open pancreatoduodenectomy (OPD) (12.1 vs 16.0 days RMET, difference -3.9 days, P<0.001), with similar morbidity (31.1% vs 36.1%) and lower Clavien-Dindo grade II+ complications (23.5% vs 34.4%).
ContextThis RCT provides level 1 evidence that RPD is non-inferior to OPD in both safety and recovery outcomes, supporting its adoption in tertiary centers with robotic expertise.
Clinical takeawayNo clinical action yet: pancreatic PDFF thresholds require validation and interventions targeting fatty pancreas remain unproven. Awareness of association supports monitoring for cardiometabolic conditions in high-risk patients.
What it foundModerate-to-severe fatty pancreas (≥16% PDFF) increased risk of incident T2D (HR 2.72), CKD (HR 1.82), and MACE (HR 1.30) vs. normal pancreas (<6% PDFF); mild fatty pancreas (6-16% PDFF) also increased T2D (HR 2.19) and MACE (HR 1.29) risk.
ContextRefines prior heterogeneous definitions of fatty pancreas by using standardized PDFF thresholds, confirming its role in the cardiometabolic risk continuum independent of obesity/visceral fat.
United European gastroenterology journal · PubMed ↗
New evidenceprospective cohort · n=142 · Jul 6, 2026
Clinical takeawayThe phase IIIb TOURMALINE study reports preliminary safety and efficacy of durvalumab with various gemcitabine-based regimens in advanced biliary tract cancer; further phase III confirmation is needed before clinical adoption.
What it foundDurvalumab plus gemcitabine-based chemotherapy regimens showed manageable safety (50.7% Grade 3/4 PRAEs) and efficacy (median OS 13.50 months, ORR 33.1%) in advanced biliary tract cancer.
ContextThis study expands on TOPAZ-1 by evaluating durvalumab with seven gemcitabine-based regimens, confirming its feasibility and efficacy in a broader, real-world population with advanced biliary tract cancer.
Clinical takeawayNo need to prefer dye over virtual chromoendoscopy for dysplasia detection in IBD surveillance, as both methods perform similarly. Choose based on availability, cost, or operator preference.
What it foundNo significant difference in dysplasia detection odds between dye chromoendoscopy and virtual chromoendoscopy in IBD patients (meta-analysis of 8 RCTs).
ContextConfirms prior evidence that virtual chromoendoscopy is non-inferior to dye chromoendoscopy for dysplasia detection, simplifying IBD surveillance strategies.
Clinical takeawayConsider CADe for endoscopists with lower baseline ADR (<54.5%) in surveillance colonoscopy, as it improves detection in this subgroup. For high-performing endoscopists, CADe does not provide additional benefit.
What it foundCADe did not increase overall adenoma detection rate (ADR) in surveillance colonoscopy (57.4% vs 58.8%; aRR 1.02 [95% CI 0.95-1.10]), but improved ADR among lower-performing endoscopists (ADR<54.5%) (45.5% vs 52.1%; aRR 1.15 [95% CI 1.01-1.30]).
ContextThis challenges the assumption that CADe universally improves ADR in surveillance colonoscopy, showing its benefit is limited to lower-performing endoscopists in a high-performing screening program.
Clinical takeawayRecognize current EUS-RFA practices lack standardization, particularly for indications beyond insulinoma, power settings, and duct-adjacent lesions (≤1mm). No immediate practice change: survey highlights need for consensus.
What it foundSurvey reveals high variability in EUS-RFA practices: 94.1% use it for insulinoma, but technique, prophylaxis (57.5% use antibiotics), power settings, and follow-up definitions vary widely.
ContextChallenges prior assumptions of uniform EUS-RFA adoption; confirms widespread procedural heterogeneity in sedation (96.3% use deep/general), risk assessment (97.5% avoid main duct involvement), and success definitions.
Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society · PubMed ↗
Clinical takeawayNo direct clinical action specified: the abstract is a practice guideline title without data; await full text for adverse event rates and recommendations.
What it foundThe abstract does not provide specific quantitative results on adverse event rates or comparisons.
ContextThis appears to be a guideline publication aiming to summarize or update standards on ERCP-related adverse events, but without the abstract providing details, it cannot be placed against prior evidence.
Clinical takeawayUnderwater immersion (U-POEM) may reduce post-procedural pain and opioid requirements vs CO2-POEM in achalasia type I/II, though larger trials are needed before protocol changes
What it foundU-POEM reduced immediate post-procedure pain scores compared to CO2-POEM (mean NPRS 1.6 vs. 3.3), cut moderate-severe pain incidence (16.7% vs. 55.5%), and lowered opioid use (5.5% vs. 50%).
ContextChallenges current standard CO2-POEM by demonstrating improved pain outcomes without compromising efficacy or safety in a randomized multicenter trial.
Clinical takeawayConsider elobixibat as a second-line therapy for functional constipation refractory to first-line treatment, particularly for patients prioritizing symptom relief and quality-of-life improvement.
What it foundElobixibat achieved a sustained complete spontaneous bowel movement (CSBM) response in 55.6% of patients vs. 33.9% with prucalopride (p=0.024).
ContextThis study directly compares two second-line therapies with distinct mechanisms, addressing a gap in evidence-based decision-making for functional constipation.
Clinical takeawayRome V criteria show lower sensitivity (66.1%) compared to Rome IV (78.9%) and Rome III (87.5%) in this secondary care study. No clinical action yet; await further validation and SOC updates.
What it foundRome V criteria for IBS had sensitivity of 66.1% (95% CI 62.1-69.9) and specificity of 80.1% (72.4-86.5), identifying a different patient group compared to Rome IV (sensitivity 78.9%, specificity 81.0%) and Rome III (sensitivity 87.5%, specificity 75.0%).
ContextRome V shifts diagnostic balance versus Rome IV (higher specificity, lower sensitivity) and Rome III (higher specificity, much lower sensitivity). This challenges prior reliance on Rome criteria alone for case identification in referrals.
The lancet. Gastroenterology & hepatology · PubMed ↗
Clinical takeawayNo clinical action yet: the study challenges the diagnostic relevance of the ≥70% RGE threshold but does not propose alternative criteria or management changes. Do not alter practice based on this alone.
What it foundOnly 3.9% of patients with accelerated gastric emptying (≥30% at 1h) met the conventional RGE threshold (≥70% at 1h), and clinical characteristics/management did not differ across emptying rates (30-49%, 50-69%, ≥70%).
ContextChallenges the clinical utility of the current ≥70% RGE threshold, as patients below this cutoff had similar symptoms and management. Prior consensus defined RGE as ≥70% at 1h by GES.
Clinical takeawayNo clinical action yet: a review of mechanistic evidence and potential interventions in preclinical or early human studies. Consider discussing dietary and probiotic strategies for gut barrier support in patients with disorders of gut-brain interaction, but await clinical trial validation.
What it foundShort-chain fatty acids, amino acids (glutamine and tryptophan), and targeted probiotics enhance tight junction integrity and mucin secretion, while psychological stress, low-fiber diets, and high-fat diets disrupt gut barrier function.
ContextConfirms and refines the growing recognition of gut barrier dysfunction in disorders of gut-brain interaction but highlights the lack of validated clinical interventions targeting barrier restoration.
The lancet. Gastroenterology & hepatology · PubMed ↗
Clinical takeawayAcupuncture may improve IBS symptoms compared to sham, but the high heterogeneity and low certainty of evidence limit clinical applicability. Discuss these limitations if patients inquire about acupuncture.
What it foundAcupuncture improved IBS response rate by 61% vs sham (RR 1.61, 95% CI 1.25-2.07) and reduced symptom severity (SMD 0.79, 95% CI 0.30-1.28) at end of treatment.
ContextThis meta-analysis provides stronger evidence for acupuncture's efficacy in IBS compared to prior inconsistent findings, though heterogeneity and low certainty remain limitations.
Clinical takeawayThe full LST subtype system has only fair inter-observer reliability (kappa about 0.36) versus moderate (about 0.48) for a simplified granular vs non-granular split, so weight the reproducible split but still document the high-risk nodular-mixed and pseudodepressed features, since guidelines use them to select en-bloc resection or ESD.
What it foundInter-observer agreement for LST classification was poor (κ=0.37 first round, κ=0.36 second round), improving to moderate (κ≈0.48) with a simplified 3-category granular vs non-granular model.
ContextChallenges current reliance on detailed LST subclassification, which lacks standardized reliability despite widespread use in predicting submucosal invasion risk and resection strategy.
The American journal of gastroenterology · PubMed ↗
Clinical takeawayIn two eradication trials, H. pylori treatment was linked to lower CRC risk mainly in genetically high-risk or virulence-factor-positive subgroups, an interesting hypothesis but not yet practice: H. pylori is not a CRC-prevention target, and infected patients should still be offered eradication on standard gastric indications regardless of genetic or virulence status.
What it foundH. pylori-positive individuals not treated with antibiotics had a higher CRC risk (SIT: HR=2.96; MITS: HR=1.27), with the greatest risk in those seropositive for four H. pylori antigens (CagA, HpaA, Omp, HP0305) or in the top decile of Polygenic Risk Score.
ContextConfirms prior observational links between H. pylori and CRC but refines by identifying high-risk subgroups (genetic predisposition, specific virulence factors) where treatment may reduce risk. Challenges the assumption of uniform benefit from H. pylori eradication for CRC prevention.
Clinical takeawayIn immunocompetent patients with mild, CT-confirmed uncomplicated left-sided diverticulitis who are non-toxic (no SIRS, CRP under 140 mg/L, WBC under 15), tolerating oral intake, and safe for outpatient care, manage without antibiotics; reserve antibiotics for immunocompromise, frailty, significant comorbidity, systemic inflammation, or refractory symptoms.
What it foundComputed tomography imaging is essential for diverticulitis diagnosis, especially at first presentation or in severe cases; colonoscopy post-recovery is recommended for complicated cases and suggested for uncomplicated cases with alarm symptoms or inadequate CRC screening.
ContextRefines prior practice by deprioritizing antibiotics for low-risk uncomplicated cases (supported by RCTs) and clarifying imaging/colonoscopy roles. Challenges historical dietary restrictions (e.g., nuts/seeds). Confirms surgery referral for select recurrent cases.
The American journal of gastroenterology · PubMed ↗
Clinical takeawayFor women with severe pelvic/GI symptoms and suspected endometriosis (e.g., dysmenorrhea, dyspareunia), evaluate for rectosigmoid endometriosis via transvaginal ultrasound or MRI. First-line hormonal therapy (OCPs/progestogens) may help symptoms; surgery only for confirmed obstruction/severe refractory cases.
What it foundBowel endometriosis affects 8-12% of women with endometriosis, primarily in the rectosigmoid colon, and diagnostic delays often exceed 7-10 years.
ContextThis review confirms the multifactorial pathogenesis and diagnostic challenges of bowel endometriosis, aligning with current practice of using imaging for diagnosis and reserving surgery for severe cases.
The lancet. Gastroenterology & hepatology · PubMed ↗
Clinical takeawayFor older adults (≥80y) with high-risk T1 CRC, weigh delayed oncologic benefit (10+ years) against immediate surgical risks; consider pathologic risk, frailty, comorbidity, and competing mortality. Avoid routine additional surgery in frail or comorbid patients.
What it foundMeta-analysis shows the survival advantage of additional surgery for T1 CRC in older adults (≥80y) only becomes evident after 10 years, while perioperative morbidity occurs immediately.
ContextRefines prior standard of recommending additional surgery for all high-risk T1 CRC by showing age-specific trade-offs in competing mortality.
Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society · PubMed ↗
Clinical takeawayMonitor phosphorus levels in critically ill ICU patients, particularly those with hyperphosphatemia, due to its association with higher mortality. No specific intervention is recommended yet due to low-quality evidence and high heterogeneity.
What it foundHyperphosphatemia was associated with increased ICU mortality (RR: 1.21) and hospital mortality (RR: 2.10), while hypophosphatemia was linked to prolonged ICU stay (+1.53 days) and mechanical ventilation duration (+1.54 days).
ContextConfirms prior concerns about phosphate abnormalities in ICU patients but refines understanding by quantifying associations with specific outcomes. Current practice lacks standardized phosphate monitoring protocols in this setting.
JPEN. Journal of parenteral and enteral nutrition · PubMed ↗
Clinical takeawayNo clinical action yet: a mechanistic review of small-intestinal zonation in nutrient absorption and disease targeting.
What it foundThe paper presents a refined model of nutrient absorption's functional landscape across the small intestine, integrating molecular and physiological data.
ContextThis review confirms and refines the understanding of small-intestinal regionalization, integrating epigenetic, transcriptional, and physiological data to explain nutrient absorption and disease patterns.
Clinical takeawayWhen evaluating patients with self-reported NCGS, assess for comorbid DGBI and ARFID symptoms, particularly in those with high psychological distress, somatic symptom reporting, increased healthcare utilization, and reduced quality of life.
What it found14.2% of adults self-reported NCGS, and 69.4% of these individuals had concomitant DGBI and/or ARFID symptoms, with 24.0% meeting criteria for all three conditions.
ContextThis study highlights the overlap between self-reported NCGS, DGBI, and ARFID, suggesting NCGS may be part of a broader syndrome of food-related symptom attribution rather than gluten-specific pathology.
United European gastroenterology journal · PubMed ↗
Clinical takeawayBe aware that DH prevalence in CD is ~6.8% overall (higher in adults, lower in children), but no change to current diagnostic practice is recommended.
What it foundPooled prevalence of dermatitis herpetiformis (DH) in celiac disease (CD) patients was 6.8% (95% CI: 5.0-9.3), with lower prevalence in pediatric CD (2.6%) than in adults (8.6%).
ContextThis meta-analysis provides pooled estimates of DH prevalence in CD (6.8%, 95% CI:5.0-9.3), clarifying higher adult (8.6%) vs pediatric (2.6%) rates, but with very high heterogeneity.
United European gastroenterology journal · PubMed ↗
A vetted, curated weekly read that turns the flood of GI literature into a short list
of what is worth knowing, grouped by subspecialty and placed in context, in a standard
format, so a busy gastroenterologist can absorb the week in about a minute.
Which journals we scan
We scan the top GI and hepatology journals and the leading general-medicine journals
(Gut, Gastroenterology, Journal of Hepatology, CGH, AJG, GIE, NEJM, Lancet, JAMA, and
peers). Journal standing is a real quality signal, so it is factored into ranking: a
finding in a flagship journal is weighted above the same finding in a minor one, capped
so prestige never dominates the actual evidence.
How each paper is labeled
Every card carries a contribution type, why the paper matters:
practice-changing, new therapy, new evidence on an open question,
basic science, diagnostic / biomarker, epidemiology, or
guideline / review. Alongside it, an evidence dot-meter, the study design, and the
sample size show how strong the finding is at a glance.
Curation
The pipeline does the first pass, filter, classify, draft, and a physician editor vets
the result before it is published. You only see what the editor stands behind.
Edited by Simon Mathews, MD.